During the six-month therapeutic period, the prevalence of heart failure medications remained unchanged in the whole cohort (p = 1.0 for beta-blockers, renin–angiotensin system inhibitors, and mineralocorticoid receptor antagonists; p = 0.50 for sodium–glucose co-transporter 2 inhibitors). Here, NR3C2 is linked to heart failure.